Paulo Jose Martins Bispo, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endophthalmitis | 15 | 2023 | 257 | 3.260 |
Why?
|
Eye Infections, Bacterial | 14 | 2023 | 239 | 3.190 |
Why?
|
Keratitis | 8 | 2023 | 239 | 2.480 |
Why?
|
Eye Infections | 4 | 2023 | 62 | 2.200 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 7 | 2024 | 695 | 2.040 |
Why?
|
Staphylococcal Infections | 9 | 2024 | 1405 | 1.850 |
Why?
|
Eye Infections, Fungal | 5 | 2023 | 100 | 1.790 |
Why?
|
Corneal Ulcer | 6 | 2023 | 128 | 1.710 |
Why?
|
Microbial Sensitivity Tests | 18 | 2024 | 1952 | 1.520 |
Why?
|
RNA, Ribosomal, 16S | 7 | 2024 | 1006 | 1.080 |
Why?
|
DNA, Bacterial | 7 | 2023 | 1455 | 0.970 |
Why?
|
Staphylococcus epidermidis | 3 | 2014 | 122 | 0.900 |
Why?
|
Treponema pallidum | 1 | 2023 | 47 | 0.890 |
Why?
|
Anti-Bacterial Agents | 22 | 2024 | 7400 | 0.890 |
Why?
|
Anti-Infective Agents | 3 | 2024 | 982 | 0.850 |
Why?
|
Achromobacter | 1 | 2021 | 8 | 0.760 |
Why?
|
Conjunctivitis | 2 | 2022 | 155 | 0.750 |
Why?
|
Aqueous Humor | 4 | 2016 | 154 | 0.750 |
Why?
|
Polymerase Chain Reaction | 8 | 2023 | 6067 | 0.740 |
Why?
|
Syphilis | 1 | 2023 | 240 | 0.730 |
Why?
|
Drug Resistance, Bacterial | 10 | 2024 | 1054 | 0.730 |
Why?
|
Uveitis | 3 | 2020 | 393 | 0.720 |
Why?
|
Organ Preservation Solutions | 1 | 2021 | 100 | 0.710 |
Why?
|
Epithelium, Corneal | 1 | 2022 | 248 | 0.690 |
Why?
|
Ophthalmic Solutions | 1 | 2021 | 305 | 0.680 |
Why?
|
Drug Contamination | 1 | 2021 | 152 | 0.670 |
Why?
|
Vitreous Body | 4 | 2016 | 399 | 0.670 |
Why?
|
Fluoroquinolones | 3 | 2024 | 309 | 0.660 |
Why?
|
Limbus Corneae | 1 | 2021 | 144 | 0.660 |
Why?
|
Bacteria | 9 | 2023 | 2196 | 0.600 |
Why?
|
Eye Infections, Parasitic | 1 | 2018 | 25 | 0.600 |
Why?
|
Eye Infections, Viral | 1 | 2018 | 60 | 0.570 |
Why?
|
Cross Infection | 5 | 2020 | 1434 | 0.560 |
Why?
|
Staphylococcus | 3 | 2024 | 156 | 0.450 |
Why?
|
Antifungal Agents | 3 | 2023 | 746 | 0.430 |
Why?
|
Aza Compounds | 1 | 2012 | 34 | 0.410 |
Why?
|
Blepharitis | 1 | 2012 | 35 | 0.410 |
Why?
|
Gentian Violet | 2 | 2011 | 29 | 0.400 |
Why?
|
Phenazines | 2 | 2011 | 56 | 0.400 |
Why?
|
Macrolides | 2 | 2024 | 206 | 0.390 |
Why?
|
Gram-Positive Bacteria | 2 | 2011 | 178 | 0.380 |
Why?
|
Multilocus Sequence Typing | 4 | 2020 | 100 | 0.360 |
Why?
|
Gram-Negative Bacteria | 2 | 2011 | 272 | 0.360 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2880 | 0.350 |
Why?
|
Oxazolidinones | 2 | 2020 | 97 | 0.340 |
Why?
|
Candida albicans | 3 | 2022 | 378 | 0.340 |
Why?
|
Molecular Typing | 2 | 2023 | 116 | 0.310 |
Why?
|
Keratoplasty, Penetrating | 3 | 2021 | 144 | 0.310 |
Why?
|
Mycobacterium chelonae | 1 | 2018 | 12 | 0.310 |
Why?
|
Bacterial Typing Techniques | 4 | 2023 | 260 | 0.300 |
Why?
|
Bacteriological Techniques | 4 | 2021 | 279 | 0.290 |
Why?
|
Water Microbiology | 1 | 2018 | 115 | 0.280 |
Why?
|
Molecular Epidemiology | 2 | 2023 | 469 | 0.280 |
Why?
|
Biofilms | 2 | 2016 | 622 | 0.280 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2018 | 84 | 0.280 |
Why?
|
Quinolines | 1 | 2012 | 759 | 0.270 |
Why?
|
Herpesvirus 3, Human | 2 | 2018 | 159 | 0.270 |
Why?
|
Cataract Extraction | 2 | 2016 | 466 | 0.260 |
Why?
|
Herpesvirus 2, Human | 2 | 2018 | 190 | 0.260 |
Why?
|
Staphylococcus aureus | 3 | 2024 | 1462 | 0.250 |
Why?
|
Streptococcus pneumoniae | 3 | 2022 | 732 | 0.250 |
Why?
|
Dexamethasone | 1 | 2012 | 1928 | 0.240 |
Why?
|
Lenses, Intraocular | 1 | 2016 | 138 | 0.240 |
Why?
|
Lens Implantation, Intraocular | 1 | 2016 | 190 | 0.230 |
Why?
|
DNA, Ribosomal | 2 | 2021 | 285 | 0.230 |
Why?
|
Brazil | 9 | 2021 | 1214 | 0.220 |
Why?
|
Streptococcus | 1 | 2024 | 198 | 0.220 |
Why?
|
Candida tropicalis | 1 | 2022 | 6 | 0.220 |
Why?
|
Amphotericin B | 1 | 2023 | 141 | 0.210 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2023 | 761 | 0.210 |
Why?
|
Glucocorticoids | 1 | 2012 | 2143 | 0.210 |
Why?
|
Azithromycin | 1 | 2024 | 201 | 0.210 |
Why?
|
Vancomycin | 2 | 2022 | 503 | 0.200 |
Why?
|
Enterococcus faecalis | 2 | 2020 | 247 | 0.200 |
Why?
|
Bacteremia | 3 | 2015 | 979 | 0.200 |
Why?
|
Otitis Media with Effusion | 1 | 2023 | 114 | 0.200 |
Why?
|
Mouth | 1 | 2024 | 380 | 0.200 |
Why?
|
Yeasts | 1 | 2022 | 279 | 0.200 |
Why?
|
Herpesvirus 1, Human | 2 | 2018 | 753 | 0.200 |
Why?
|
Toxoplasmosis, Ocular | 2 | 2019 | 29 | 0.190 |
Why?
|
Corynebacterium Infections | 1 | 2021 | 27 | 0.190 |
Why?
|
Bacterial Infections | 3 | 2019 | 1402 | 0.190 |
Why?
|
Cornea | 2 | 2020 | 1325 | 0.190 |
Why?
|
Eye Banks | 1 | 2021 | 40 | 0.180 |
Why?
|
Fusarium | 1 | 2020 | 51 | 0.180 |
Why?
|
Sensitivity and Specificity | 5 | 2023 | 14656 | 0.180 |
Why?
|
Staphylococcal Skin Infections | 1 | 2021 | 78 | 0.180 |
Why?
|
Vaccines, Conjugate | 1 | 2022 | 328 | 0.180 |
Why?
|
Humans | 45 | 2024 | 760261 | 0.180 |
Why?
|
Toxoplasma | 2 | 2019 | 151 | 0.180 |
Why?
|
Metagenomics | 2 | 2020 | 457 | 0.170 |
Why?
|
Community-Acquired Infections | 2 | 2021 | 461 | 0.170 |
Why?
|
Enterococcus faecium | 1 | 2020 | 101 | 0.170 |
Why?
|
Aspergillus fumigatus | 1 | 2020 | 156 | 0.170 |
Why?
|
Povidone-Iodine | 1 | 2019 | 55 | 0.160 |
Why?
|
Neglected Diseases | 1 | 2019 | 66 | 0.160 |
Why?
|
Soft Tissue Infections | 1 | 2021 | 168 | 0.160 |
Why?
|
Middle Aged | 17 | 2024 | 220175 | 0.160 |
Why?
|
Massachusetts | 2 | 2023 | 8805 | 0.160 |
Why?
|
Inflammasomes | 1 | 2023 | 532 | 0.160 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2021 | 244 | 0.160 |
Why?
|
Disease Outbreaks | 1 | 2018 | 1759 | 0.150 |
Why?
|
Pneumococcal Vaccines | 1 | 2022 | 397 | 0.150 |
Why?
|
Polymyxin B | 2 | 2020 | 44 | 0.150 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2018 | 95 | 0.150 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2020 | 343 | 0.150 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2018 | 37 | 0.150 |
Why?
|
Tissue and Organ Harvesting | 1 | 2021 | 377 | 0.150 |
Why?
|
Keratitis, Dendritic | 1 | 2017 | 18 | 0.150 |
Why?
|
Tissue Donors | 3 | 2021 | 2314 | 0.140 |
Why?
|
Genotype | 3 | 2023 | 12959 | 0.140 |
Why?
|
Male | 19 | 2024 | 359413 | 0.130 |
Why?
|
Drug Combinations | 3 | 2021 | 2024 | 0.130 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 642 | 0.130 |
Why?
|
Adult | 13 | 2024 | 219847 | 0.120 |
Why?
|
Sequence Analysis, DNA | 2 | 2023 | 4717 | 0.120 |
Why?
|
Hospitals | 3 | 2020 | 3929 | 0.120 |
Why?
|
Conjunctivitis, Bacterial | 1 | 2014 | 22 | 0.120 |
Why?
|
Genes, Bacterial | 2 | 2020 | 1070 | 0.120 |
Why?
|
Candidemia | 1 | 2015 | 38 | 0.120 |
Why?
|
Herpes Simplex | 1 | 2018 | 477 | 0.120 |
Why?
|
Aged | 13 | 2024 | 168995 | 0.120 |
Why?
|
DNA Topoisomerase IV | 1 | 2013 | 42 | 0.110 |
Why?
|
DNA, Fungal | 1 | 2014 | 275 | 0.110 |
Why?
|
Mycobacterium Infections | 1 | 2014 | 121 | 0.110 |
Why?
|
DNA Primers | 1 | 2018 | 2819 | 0.110 |
Why?
|
Cytomegalovirus | 1 | 2018 | 756 | 0.110 |
Why?
|
Methicillin Resistance | 1 | 2014 | 199 | 0.110 |
Why?
|
DNA Gyrase | 1 | 2013 | 85 | 0.110 |
Why?
|
Female | 16 | 2024 | 391011 | 0.100 |
Why?
|
Mycobacterium | 1 | 2014 | 250 | 0.100 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2014 | 586 | 0.100 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 2 | 2018 | 144 | 0.100 |
Why?
|
Fungi | 1 | 2014 | 338 | 0.100 |
Why?
|
Cations | 1 | 2012 | 239 | 0.100 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2013 | 238 | 0.090 |
Why?
|
Cytomegalovirus Infections | 1 | 2018 | 831 | 0.090 |
Why?
|
Trimethoprim | 2 | 2021 | 85 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3618 | 0.090 |
Why?
|
Pseudomonas Infections | 2 | 2015 | 623 | 0.090 |
Why?
|
Culture Media | 1 | 2012 | 899 | 0.090 |
Why?
|
Pneumococcal Infections | 1 | 2014 | 503 | 0.090 |
Why?
|
Phacoemulsification | 1 | 2011 | 149 | 0.080 |
Why?
|
Plasmids | 1 | 2014 | 2277 | 0.080 |
Why?
|
Drug Resistance | 1 | 2014 | 1617 | 0.070 |
Why?
|
Lasers, Excimer | 1 | 2018 | 69 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5790 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 2 | 2012 | 1275 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2024 | 22041 | 0.070 |
Why?
|
Aged, 80 and over | 7 | 2018 | 58947 | 0.070 |
Why?
|
Lens Capsule, Crystalline | 1 | 2016 | 39 | 0.070 |
Why?
|
Pseudophakia | 1 | 2016 | 60 | 0.070 |
Why?
|
Swine | 3 | 2020 | 5902 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2011 | 558 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2023 | 80301 | 0.060 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2016 | 941 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2563 | 0.060 |
Why?
|
Toll-Like Receptor 1 | 1 | 2023 | 49 | 0.060 |
Why?
|
Caspase 1 | 1 | 2023 | 226 | 0.050 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2008 | 1129 | 0.050 |
Why?
|
Middle Ear Ventilation | 1 | 2023 | 99 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2011 | 1529 | 0.050 |
Why?
|
Polymyxins | 1 | 2021 | 19 | 0.050 |
Why?
|
Toll-Like Receptor 2 | 1 | 2023 | 348 | 0.050 |
Why?
|
Corynebacterium | 1 | 2021 | 47 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4573 | 0.050 |
Why?
|
Benzalkonium Compounds | 1 | 2020 | 21 | 0.050 |
Why?
|
Ear, Middle | 1 | 2023 | 337 | 0.050 |
Why?
|
Contact Lenses, Hydrophilic | 1 | 2020 | 54 | 0.050 |
Why?
|
Goblet Cells | 1 | 2023 | 299 | 0.040 |
Why?
|
Argentina | 1 | 2021 | 245 | 0.040 |
Why?
|
Eye Evisceration | 1 | 2019 | 22 | 0.040 |
Why?
|
Onchocerciasis, Ocular | 1 | 2019 | 7 | 0.040 |
Why?
|
Trachoma | 1 | 2019 | 18 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3774 | 0.040 |
Why?
|
Eye Enucleation | 1 | 2019 | 128 | 0.040 |
Why?
|
Corneal Perforation | 1 | 2019 | 29 | 0.040 |
Why?
|
Latin America | 1 | 2021 | 405 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20048 | 0.040 |
Why?
|
Young Adult | 5 | 2018 | 58673 | 0.040 |
Why?
|
Leprosy | 1 | 2019 | 129 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13967 | 0.040 |
Why?
|
Adolescent | 6 | 2018 | 87747 | 0.040 |
Why?
|
Herpesviridae | 1 | 2019 | 106 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2012 | 12412 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2023 | 999 | 0.040 |
Why?
|
Animals | 4 | 2022 | 167940 | 0.040 |
Why?
|
Herpesviridae Infections | 1 | 2019 | 270 | 0.040 |
Why?
|
Prostheses and Implants | 1 | 2023 | 1272 | 0.030 |
Why?
|
DNA Probes | 1 | 2017 | 551 | 0.030 |
Why?
|
Phylogeography | 1 | 2014 | 72 | 0.030 |
Why?
|
Fungemia | 1 | 2015 | 58 | 0.030 |
Why?
|
RNA, Ribosomal, 18S | 1 | 2014 | 57 | 0.030 |
Why?
|
Acinetobacter Infections | 1 | 2015 | 71 | 0.030 |
Why?
|
Sepsis | 1 | 2008 | 2594 | 0.030 |
Why?
|
Adhesins, Bacterial | 1 | 2014 | 118 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 2014 | 328 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2014 | 131 | 0.030 |
Why?
|
Klebsiella | 1 | 2013 | 52 | 0.030 |
Why?
|
Bacterial Capsules | 1 | 2014 | 242 | 0.030 |
Why?
|
Klebsiella Infections | 1 | 2015 | 147 | 0.030 |
Why?
|
Acinetobacter | 1 | 2013 | 39 | 0.030 |
Why?
|
Agar | 1 | 2012 | 55 | 0.030 |
Why?
|
DNA, Viral | 1 | 2019 | 2195 | 0.030 |
Why?
|
Multigene Family | 1 | 2014 | 1079 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2019 | 879 | 0.020 |
Why?
|
Virulence Factors | 1 | 2014 | 508 | 0.020 |
Why?
|
Acinetobacter baumannii | 1 | 2012 | 115 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 2015 | 524 | 0.020 |
Why?
|
Gene Amplification | 1 | 2014 | 1085 | 0.020 |
Why?
|
Genome, Bacterial | 1 | 2014 | 770 | 0.020 |
Why?
|
Prospective Studies | 4 | 2017 | 54263 | 0.020 |
Why?
|
Child | 5 | 2017 | 79758 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2015 | 26168 | 0.020 |
Why?
|
Hospitals, University | 1 | 2010 | 568 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15680 | 0.020 |
Why?
|
RNA, Ribosomal | 1 | 2008 | 226 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2208 | 0.020 |
Why?
|
Phylogeny | 1 | 2014 | 2775 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5039 | 0.020 |
Why?
|
Developing Countries | 1 | 2019 | 2880 | 0.020 |
Why?
|
Infant | 3 | 2015 | 36030 | 0.020 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2013 | 833 | 0.020 |
Why?
|
Child, Preschool | 3 | 2015 | 42034 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9283 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2008 | 956 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1266 | 0.020 |
Why?
|
Genetic Variation | 1 | 2018 | 6540 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3568 | 0.010 |
Why?
|
Escherichia coli | 1 | 2014 | 4223 | 0.010 |
Why?
|
Visual Acuity | 1 | 2011 | 2635 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10185 | 0.010 |
Why?
|
United States | 2 | 2020 | 72363 | 0.010 |
Why?
|
Risk Factors | 2 | 2019 | 74269 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39254 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 25928 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15687 | 0.010 |
Why?
|
Incidence | 1 | 2010 | 21378 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2010 | 64947 | 0.000 |
Why?
|